Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Structural and Functional Remodeling of the Left Atrium: Clinical and Therapeutic Implications for Atrial Fibrillation.

Pathak R, Lau DH, Mahajan R, Sanders P.

J Atr Fibrillation. 2013 Dec 31;6(4):986. doi: 10.4022/jafib.986. eCollection 2013 Dec. Review.

2.

A Novel Transgenic Mouse Model of Cardiac Hypertrophy and Atrial Fibrillation.

Rosenberg MA, Das S, Quintero Pinzon P, Knight AC, Sosnovik DE, Ellinor PT, Rosenzweig A.

J Atr Fibrillation. 2012 Feb 2;4(5):415. doi: 10.4022/jafib.415. eCollection 2012 Feb-Mar. Review.

3.

Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Seccia TM, Caroccia B, Adler GK, Maiolino G, Cesari M, Rossi GP.

Hypertension. 2017 Apr;69(4):545-550. doi: 10.1161/HYPERTENSIONAHA.116.08956. Review. No abstract available.

PMID:
28264920
4.

Early Changes in Atrial Electromechanical Coupling in Patients with Hypertension: Assessment by Tissue Doppler Imaging.

Avci BK, Gulmez O, Donmez G, Pehlivanoglu S.

Chin Med J (Engl). 2016 Jun 5;129(11):1311-5. doi: 10.4103/0366-6999.182846.

5.

Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels.

Ogunsua AA, Shaikh AY, Ahmed M, McManus DD.

Methodist Debakey Cardiovasc J. 2015 Oct-Dec;11(4):228-34. doi: 10.14797/mdcj-11-4-228. Review.

6.

Clinical Diagnosis of Electrical Versus Anatomic Left Ventricular Hypertrophy: Prognostic and Therapeutic Implications.

Aro AL, Chugh SS.

Circ Arrhythm Electrophysiol. 2016 Apr;9(4):e003629. doi: 10.1161/CIRCEP.115.003629. Review. No abstract available.

7.

The Association between the PR Interval and Left Ventricular Measurements in the Multiethnic Study of Atherosclerosis.

Husby MP, Soliman EZ, Goldberger JJ, Liu K, Lloyd-Jones D, Durazo-Arvizu R, Kramer H.

Cardiol Res Pract. 2015;2015:193698. doi: 10.1155/2015/193698. Epub 2015 Oct 19.

8.

50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study.

Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D.

Lancet. 2015 Jul 11;386(9989):154-62. doi: 10.1016/S0140-6736(14)61774-8. Epub 2015 May 7.

9.

Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013.

Van Wagoner DR, Piccini JP, Albert CM, Anderson ME, Benjamin EJ, Brundel B, Califf RM, Calkins H, Chen PS, Chiamvimonvat N, Darbar D, Eckhardt LL, Ellinor PT, Exner DV, Fogel RI, Gillis AM, Healey J, Hohnloser SH, Kamel H, Lathrop DA, Lip GY, Mehra R, Narayan SM, Olgin J, Packer D, Peters NS, Roden DM, Ross HM, Sheldon R, Wehrens XH.

Heart Rhythm. 2015 Jan;12(1):e5-e29. doi: 10.1016/j.hrthm.2014.11.011. Epub 2014 Nov 18. No abstract available.

10.

The early stage of the atrial electroanatomic remodeling as substrates for atrial fibrillation in hypertensive patients.

Yin X, Zhao Y, Xi Y, Cheng N, Xia Y, Zhang S, Dong Y, Chang D, Cheng J, Yang Y, Gao L.

J Am Heart Assoc. 2014 Sep 18;3(5):e001033. doi: 10.1161/JAHA.114.001033. Erratum in: J Am Heart Assoc. 2015 Apr;4(4). pii: e000653. doi: 10.1161/JAHA.115.000653.

11.

Cardiovascular remodeling during long-term nocturnal home hemodialysis.

Friesen T, Jassal DS, Zhu M, Eng F, Rigatto C, Tangri N, Sood MM, Karlstedt E, Premecz S, Komenda P.

Clin Exp Nephrol. 2015 Jun;19(3):514-20. doi: 10.1007/s10157-014-0992-z. Epub 2014 Jun 4.

12.

A Novel Transgenic Mouse Model of Cardiac Hypertrophy and Atrial Fibrillation.

Rosenberg MA, Das S, Pinzon PQ, Knight AC, Sosnovik DE, Ellinor PT, Rosenzweig A.

J Atr Fibrillation. 2012 Feb;2(9):1-15.

13.

Results of clinical application of the modified maze procedure as concomitant surgery.

Bakker RC, Akin S, Rizopoulos D, Kik C, Takkenberg JJ, Bogers AJ.

Interact Cardiovasc Thorac Surg. 2013 Feb;16(2):151-6. doi: 10.1093/icvts/ivs440. Epub 2012 Oct 26.

14.

Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease.

Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC, Struthers AD.

J Am Soc Nephrol. 2011 Jul;22(7):1382-9. doi: 10.1681/ASN.2010111185. Epub 2011 Jun 30.

15.

Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the Utah obesity study.

Owan T, Avelar E, Morley K, Jiji R, Hall N, Krezowski J, Gallagher J, Williams Z, Preece K, Gundersen N, Strong MB, Pendleton RC, Segerson N, Cloward TV, Walker JM, Farney RJ, Gress RE, Adams TD, Hunt SC, Litwin SE.

J Am Coll Cardiol. 2011 Feb 8;57(6):732-9. doi: 10.1016/j.jacc.2010.10.017.

16.

Comparing angiotensin II receptor blockers on benefits beyond blood pressure.

Siragy HM.

Adv Ther. 2010 May;27(5):257-84. doi: 10.1007/s12325-010-0028-3. Epub 2010 Jun 3. Review.

17.

Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop.

Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, Ellinor PT, Go AS, Goldschlager NF, Heckbert SR, Jalife J, Kerr CR, Levy D, Lloyd-Jones DM, Massie BM, Nattel S, Olgin JE, Packer DL, Po SS, Tsang TS, Van Wagoner DR, Waldo AL, Wyse DG.

Circulation. 2009 Feb 3;119(4):606-18. doi: 10.1161/CIRCULATIONAHA.108.825380.

18.

Current perceptions of the epidemiology of atrial fibrillation.

Kannel WB, Benjamin EJ.

Cardiol Clin. 2009 Feb;27(1):13-24, vii. doi: 10.1016/j.ccl.2008.09.015. Review.

19.

Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin.

Liu F, Levin MD, Petrenko NB, Lu MM, Wang T, Yuan LJ, Stout AL, Epstein JA, Patel VV.

J Mol Cell Cardiol. 2008 Dec;45(6):715-23. doi: 10.1016/j.yjmcc.2008.08.015. Epub 2008 Sep 16.

Supplemental Content

Support Center